Solid Biosciences Inc. Share Price & Technical Analysis
SLDB · $6.88 (+3.93%)
Healthcare / Biotechnology
$6.88
+3.93%
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycar…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-10% return in May, 6% avg return in past 3 year May month.
21% return in 2026, 61% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | -3% | 20% | 0% | -10% | – | – | – | – | – | – | – | 21% |
| 25 | -20% | 81% | -34% | -13% | -3% | 53% | 42% | -18% | 15% | -11% | 2% | 6% | 98% |
| 24 | 15% | 36% | 40% | -34% | -6% | -30% | 51% | 2% | -20% | -21% | 2% | -30% | 4% |
| 23 | 41% | -25% | -16% | 4% | 27% | -16% | -19% | -14% | -31% | -8% | 22% | 118% | 82% |
| 22 | -30% | -34% | 45% | -53% | -4% | 6% | 10% | -5% | -27% | -12% | 5% | -19% | -121% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$727.77M
P/E ratio
—
52W high
$8.87
52W low
$2.83
Volume
7,89,322
Beta
2.47
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Solid Biosciences Inc. share price today?
- Solid Biosciences Inc. (SLDB) last traded around $6.88 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SLDB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SLDB. Download the app for real-time alerts.
- How can I analyze Solid Biosciences Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.